Medical Condition News

RSS

Synexus to develop effective clinical trials for Mild cognitive impairment

Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.

From AES - Accelerated Enrollment Solutions 16 Nov 2010

Medical Acoustics receives UB CAT/NYSTAR grant

Medical Acoustics LLC, a commercial-stage medical device company which employs acoustic technologies for diagnostic and therapeutic medical applications, today announced that it has been awarded a UB CAT/NYSTAR grant.

16 Nov 2010

Study shows asthma drugs can treat aortic aneurysm

A new study from the Swedish medical university Karolinska Institutet shows that asthma drugs are a potential treatment for aortic aneurysm. These drugs, which block cysteinyl-leukotrienes, could reduce the break down of vessel wall tissue and the dilation of the aortic wall, and thus the risk of its rupturing.

16 Nov 2010

Study confirms healthy lifestyle has the biggest impact on cardiovascular health

Two large studies from Northwestern Medicine confirm a healthy lifestyle has the biggest impact on cardiovascular health. One study shows the majority of people who adopted healthy lifestyle behaviors in young adulthood maintained a low cardiovascular risk profile in middle age.

16 Nov 2010

Size of hippocampus may be linked to early dementia

The size of the part of the brain known as the hippocampus may be linked to future dementia, reveals a thesis from the University of Gothenburg, Sweden.

16 Nov 2010

New mechanism breaks drug resistance in ovarian cancer

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.

16 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Epizyme announces publication of EZH2 enzyme for lymphoma in PNAS

Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, centered on the epigenetic enzyme EZH2, illuminates a clear path for the translation of basic science into targeted therapies for the safe and effective treatment of specific forms of human lymphomas.

16 Nov 2010

Researchers identify pattern of brain activity that may develop ASD

An autism study by Yale School of Medicine researchers using functional magnetic resonance imaging (fMRI) has identified a pattern of brain activity that may characterize the genetic vulnerability to developing autism spectrum disorder (ASD). Published today in the early edition of Proceedings of the National Academy of Sciences, the study could eventually lead to earlier and more accurate autism diagnosis.

16 Nov 2010

Researchers discover circadian rhythms regulate fat metabolism

UC Irvine researchers have discovered that circadian rhythms the internal body clock regulate fat metabolism. This helps explain why people burn fat more efficiently at certain times of day and could lead to new pharmaceuticals for obesity, diabetes and energy-related illnesses.

16 Nov 2010

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, today announced that it was awarded an Innovation Credit of EUR 1.3 million from the Dutch government.

16 Nov 2010

New ELISA protocol for Midkine detection in blood serum

BioGenes GmbH, a supplier of GMP compliant immunoassay and antibody services, has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum.

16 Nov 2010

New stem cell-infused patch improves heart function after myocardial infarction

University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

16 Nov 2010

Researchers develop human cell-based model of Rett syndrome

A groundbreaking study published Friday in the leading scientific journal, Cell, revealed that a team of investigators had successfully generated nerve cells using skin cells from four individuals with Rett syndrome. The study, funded in part by IRSF, was led by Dr. Alysson Muotri at the University of California, San Diego--a leading researcher in the stem cell field.

16 Nov 2010

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.

16 Nov 2010

Study finds two-thirds of asthma patients take combined ICS/LABA treatment

Despite national guidelines recommending that inhaled corticosteroid (ICS) be used alone as the preferred treatment for patients with mild persistent asthma, a new study finds that nearly two-thirds of these patients are taking more costly drugs that combine an ICS and a long-acting beta agonist (LABA) with no apparent additional clinical benefit noted based on pharmacy and medical claims.

16 Nov 2010

Merrion prepares Phase III study for Orazol in breast cancer treatment

After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

16 Nov 2010

Iron in plaque may predict risk of myocardial infarction

Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.

16 Nov 2010

Inconsistent food labels contribute to consumer uncertainty about appropriate food intake

People are easily fooled when it comes to food labels, and will eat more of something if they believe it's a "small" portion, according to a new study in the Journal of Consumer Research.

16 Nov 2010

Study finds significant variability in CPR quality between day and night

CPR quality is worse during in-hospital cardiac arrests occurring overnight than those that happen during the day, according to a new University of Pennsylvania School of Medicine study that will be presented at the American Heart Association's annual Scientific Sessions on November 14.

16 Nov 2010